APOE gene variants that may protect against Alzheimer's
Study Alzheimer's Disease Protective APOE Variants
Researchers are looking at whether rare versions of the APOE gene change how amyloid and tau harm brain cells and might protect people from Alzheimer's.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | J. David Gladstone Institutes NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11235906 on NIH RePORTER |
What this research studies
This project focuses on rare APOE gene variants, such as APOE3‑Christchurch, that appear to reduce Alzheimer's risk. Scientists will use 3‑D human cell models and animal models to compare how different APOE forms influence amyloid‑beta and tau, the two proteins linked to Alzheimer's. The work aims to uncover molecular and neural‑network mechanisms of protection rather than testing treatments on patients immediately. Results could point to new drug targets or biomarkers to identify people with natural protection.
Who could benefit from this research
Good fit: People with a family history of late‑onset Alzheimer's or known APOE risk or protective variants would be most relevant to this research.
Not a fit: Individuals whose disease is driven by non‑APOE genetic causes of early‑onset Alzheimer's or who have conditions unrelated to amyloid/tau biology may not directly benefit from these findings.
Why it matters
Potential benefit: If successful, this could reveal biological ways some people naturally resist Alzheimer's and guide new prevention or treatment strategies.
How similar studies have performed: Laboratory and animal studies have shown APOE variants affect amyloid and tau biology and a single APOE3‑Christchurch case suggested protection, but translating these findings into therapies remains largely untested.
Where this research is happening
San Francisco, United States
- J. David Gladstone Institutes — San Francisco, United States (Active)
Researchers
- Principal investigator: Huang, Yadong — J. David Gladstone Institutes
- Study coordinator: Huang, Yadong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.